Cytovation is a clinical-stage immune-oncology company that specialises in dermatological diseases.
Cytovation develops peptide products for the treatment of cutaneous warts caused by human papilloma virus (HPV).
Cytovation was started as a spin-off from the University of Bergen (Norway), in 2001. The company is headquartered in Bergen, Norway.
Cytovation is developing CyPep-1, the first synthetic peptide engineered to selectively target tumour cell membranes based on their altered molecular composition.
Cytovation's CyPep-1 is designed to eliminate cancer cells through the formation of pores in the plasma membrane, which causes the release of cancer specific antigens to the immune system.
Cytovation is bakced by Sandwater, Canica, and others. The company raised $20M (NOK 180M) in a Series A round on Jan 25, 2022. This brings Cytovation's total funding to $22.6M to date.